Novavax (NASDAQ:NVAX) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.24, RTT News reports. The firm had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $4.40 million. During the same quarter in the previous year, the firm posted ($2.40) EPS.
Shares of NASDAQ NVAX traded up $0.09 during midday trading on Friday, hitting $4.59. 858,200 shares of the company traded hands, compared to its average volume of 807,410. The firm has a market cap of $106.69 million, a P/E ratio of -0.46 and a beta of 1.90. The stock has a 50-day moving average price of $4.91 and a 200 day moving average price of $4.94. Novavax has a 12-month low of $4.01 and a 12-month high of $51.60.
A number of research firms have issued reports on NVAX. LADENBURG THALM/SH SH restated a “buy” rating and issued a $27.50 price objective on shares of Novavax in a research report on Friday. ValuEngine upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of Novavax from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. HC Wainwright boosted their price objective on shares of Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Citigroup decreased their price objective on shares of Novavax from $19.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, September 24th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $31.15.
In related news, SVP John A. Herrmann III sold 3,643 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $7.07, for a total transaction of $25,756.01. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO John Trizzino sold 5,578 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $5.72, for a total transaction of $31,906.16. Following the transaction, the chief financial officer now owns 4,800 shares in the company, valued at approximately $27,456. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,841 shares of company stock worth $117,114. 3.30% of the stock is owned by insiders.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.